To prevent the autolysis reaction caused by the binding of anti‐CD38 CAR‐T to CD38 on the cell surface, some researchers have attempted to combine CD38 antibody with anti‐CD38 CAR‐T, resulting in significant and specific tumor cell killing in both in vitro and mouse experiments.102. This evidence concerns the gene CD38 and neoplasm.